Antibody-drug conjugates remain red-hot in 2026’s biopharma M&A splurge. The overall ADC category will be worth $57 billion by 2032, according to Evaluate Pharma. Gilead’s $3 billion acquisition of Tubulis...
With over a decade at Evaluate under his belt, it seems remiss that we’ve not caught up with Paul Verdin, SVP, Head of Consulting and Analytics before now. In his...
Pharma forecasting is not a “one and done” activity. The life of a drug – from a glint in the clinician’s eye, to an established therapy heading towards loss of...
Kelly Chamberlain has been with Norstella, Evaluate’s parent company as Partner, Market Intelligence since 2024. She’s an expert in supporting competitive intelligence workflows and ensuring that CI teams can maximize...
CNS may finally be emerging from its long discussed graveyard. Oncology dealmaking is becoming more selective. And sourcing innovation from China is no longer something to be coy about. These...
For the past few years, Melanie Senior and Andreas Hadjivasiliou have worked together to deliver Evaluate’s annual Orphan Drugs report. They charted the rise and rise of drugs for rare...
